Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Summary

A retraction published in The Lancet, Volume 395, Issue 10240, p1820, dated June 13, 2020 (published online June 5, 2020), by Mandeep R Mehra, Frank Ruschitzka and Amit N Patel, asking that their May 22, 2020 article "Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis" be retracted. The authors write that concerns were raised about the data and analyses conducted by Surgisphere Corporation, whose founder Sapan Desai was a co-author. Independent reviewers withdrew after Surgisphere would not transfer the full dataset, client contracts and full ISO audit report, citing client agreements and confidentiality. "Based on this development, we can no longer vouch for the veracity of the primary data sources," the authors write, and they apologise to the editors and readers.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

Comment Volume 395 , Issue 10240 p1820 June 13, 2020

Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Mandeep R Mehra a [email protected] ∙ Frank Ruschitzka b ∙ Amit N Patel c , d

a Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, MA 02115, USA

b University Heart Center, University Hospital Zurich, Zurich, Switzerland

c Department of Biomedical Engineering, University of Utah, Salt Lake City, UT, USA

d HCA Research Institute, Nashville, TN, USA

Publication History:

Published June 5, 2020

DOI: 10.1016/S0140-6736(20)31324-6 Also available on ScienceDirect

Download started

Corrected:

RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Mandeep R Mehra, Sapan S Desai, Frank Ruschitzka et al.

May 22, 2020

Corrected:

Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

The Lancet Editors

June 3, 2020

After publication of our Lancet Article, 1 several concerns were raised with respect to the veracity of the data and analyses conducted by Surgisphere Corporation and its founder and our co-author, Sapan Desai, in our publication. We launched an independent third-party peer review of Surgisphere with the consent of Sapan Desai to evaluate the origination of the database elements, to confirm the completeness of the database, and to replicate the analyses presented in the paper.

Our independent peer reviewers informed us that Surgisphere would not transfer the full dataset, client contracts, and the full ISO audit report to their servers for analysis as such transfer would violate client agreements and confidentiality requirements. As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process.

We always aspire to perform our research in accordance with the highest ethical and professional guidelines. We can never forget the responsibility we have as researchers to scrupulously ensure that we rely on data sources that adhere to our high standards. Based on this development, we can no longer vouch for the veracity of the primary data sources. Due to this unfortunate development, the authors request that the paper be retracted.

We all entered this collaboration to contribute in good faith and at a time of great need during the COVID-19 pandemic. We deeply apologise to you, the editors, and the journal readership for any embarrassment or inconvenience that this may have caused.

MRM reports personal fees from Abbott, Medtronic, Janssen, Roivant, Triple Gene, Mesoblast, Baim Institute for Clinical Research, Portola, Bayer, NupulseCV, FineHeart, and Leviticus. FR has been paid for time spent as a committee member for clinical trials, advisory boards, other forms of consulting, and lectures or presentations; these payments were made directly to the University of Zurich and no personal payments were received in relation to these trials or other activities since 2018. Before 2018 FR reports grants and personal fees from SJM/Abbott, grants and personal fees from Servier, personal fees from Zoll, personal fees from Astra Zeneca, personal fees from Sanofi, grants and personal fees from Novartis, personal fees from Amgen, personal fees from BMS, personal fees from Pfizer, personal fees from Fresenius, personal fees from Vifor, personal fees from Roche, grants and personal fees from Bayer, personal fees from Cardiorentis, personal fees from Boehringer Ingelheim, other from Heartware, and grants from Mars. ANP declares no competing interests.

Reference

Mehra, MR ∙ Desai, SS ∙ Ruschitzka, F ∙ et al.

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Lancet. 2020; published online May 22.

10.1016/S0140-6736(20)31180-6

Crossref

Scopus (622)

Google Scholar

Related Collection

COVID-19 Collection Access the latest 2019 novel coronavirus disease (COVID-19) content from across The Lancet journals as it is published.

Article metrics

File and source

File: fulltext_9c2371cfbf.html
Size: 270,066 bytes
SHA-256: 14ad1d146ce1e199e191e2708c3f90c24d8c3a9edb29a1fe21f470afb8e57ad3
Our copy: fulltext_9c2371cfbf.html
Original: www.thelancet.com